Amboy Street Invests in Millie’s $12M Series A

Amboy Street is excited to announce its latest investment in Millie - a midwifery-led, hybrid maternity clinic providing in-person and virtual care.

Millie is a network of tech-enabled midwifery-led maternity clinics offering end-to-end patient care both in-person and online. Their offerings include prenatal care, labor and delivery support (at partner hospitals), remote pregnancy monitoring, postpartum care, patient education and gynecological care such as wellness exams, birth control, preconception counseling and miscarriage management. Millie has a flagship clinic in Berkeley, CA and will be expanding to more markets in 2025.

In recent decades, the U.S. has experienced a concerning rise in rates of maternal mortality and morbidity. Compared to other high-income countries, the U.S. has worse maternal health outcomes, with significant disparities based on race and location. Expanding access to care while enhancing actuarial ROI is critical to a functioning healthcare system. Delivering a modern, consumer-focused healthcare experience that promotes health equity and inclusion will address this need.

Millie is exemplary in their mission to improve access and outcomes. Millie enables women, regardless of insurance coverage, to receive the same high-quality, high-touch care. They accept a range of PPO and HMO plans as well as some local networks and Medi-Cal via Alameda Alliance for Health (AAH), the largest Medicaid plan in its market. Millie also demonstrates improved outcomes across maternal health conditions and has proven actuarial ROI.

Founded by Anu Sharma, Talia Borgo and Sarah Reynolds, the Millie team combines clinical, technical and regulatory expertise to drive better outcomes for mothers across the Bay Area and beyond. With providers from top tier academic medical centers like UCSF, Millie is dedicated to providing the highest quality, holistic care.

“Inspired by a near-miss following the birth of my own daughter, I set out to build a better maternity model that provides more complete, right-sized, and proactive care,” said Anu Sharma, Founder & CEO of Millie. “I’m proud that Millie is not only a women-powered team, but is also backed by an all-star women-powered cap table — evidence that women are creating and funding their own solutions to create a better system for themselves.”

Since its launch in 2022, Millie has served over 1600 women and has proven superior outcomes compared to the national average in C-section rates, NICU admission rates, preterm birth rates and mental health remission rates. Amboy Street is excited to support Millie alongside notable co-investors Foreground Capital, TMV and Pivotal Ventures. With the funding, Millie will launch  new clinics, expand care offerings, including expanded doula and postpartum support as well as  GYN offerings.

Millie is one of ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading tele-health abortion provider, Contraline, the maker of male birth control and Playground, a leading female-focused sexual wellness brand. See the full portfolio here. To learn more about Millie visit www.millieclinic.com.

Continue Reading

2021-2024: Active Acquirer Profiles in Women’s Health

We analyzed our annual Top 10 Deals blog series from 2021 - 2024 and identified the most active acquirer profiles in women’s health and sexual health.

Top 10 Deals of 2024: Ovarian Cancer Therapeutics Sold for $1.8B

For our last deal in the Top 10 Deals of 2024 series, we explore a major acquisition in women’s health biopharma - a deal that advances innovation in the treatment of ovarian cancer, one of the deadliest forms of the disease.

Amboy Street Invests in Endo Therapeutic - Gesynta Pharma’s $27M Round

Amboy Street Ventures is excited to announce its latest investment in Gesynta Pharma - developing a novel non-hormonal drug candidate for the treatment of endometriosis.

2021-2024: Active Acquirer Profiles in Women’s Health

We analyzed our annual Top 10 Deals blog series from 2021 - 2024 and identified the most active acquirer profiles in women’s health and sexual health.

Top 10 Deals of 2024: Ovarian Cancer Therapeutics Sold for $1.8B

For our last deal in the Top 10 Deals of 2024 series, we explore a major acquisition in women’s health biopharma - a deal that advances innovation in the treatment of ovarian cancer, one of the deadliest forms of the disease.

Fast track our industry.
Get in touch today.